| Dr Donald A Gajewski, MD | |
|
111 Victoria Rd, Asheville, NC 28801-4811 | |
| (828) 252-7331 | |
| Not Available |
| Full Name | Dr Donald A Gajewski |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 30 Years |
| Location | 111 Victoria Rd, Asheville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851495535 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 2015-00517 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Mission Hospital And Asheville Surgery Ce | Asheville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mission Health Community Multispecialty Providers Llc | 9537468574 | 577 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
| Entity Name | Mission Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962452482 PECOS PAC ID: 0648189969 Enrollment ID: O20040309000878 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
| Entity Name | Mission Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114150190 PECOS PAC ID: 0749326106 Enrollment ID: O20100313000054 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
| Entity Name | Mission Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548532021 PECOS PAC ID: 0648189969 Enrollment ID: O20120316000506 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
| Entity Name | Mission Health Community Multispecialty Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457719130 PECOS PAC ID: 9537468574 Enrollment ID: O20160426001883 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald A Gajewski, MD Po Box 602998, Charlotte, NC 28260-2998 Ph: () - | Dr Donald A Gajewski, MD 111 Victoria Rd, Asheville, NC 28801-4811 Ph: (828) 252-7331 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
Urologix, Inc., announced today that it received a letter, dated February 16, 2011, from The NASDAQ Stock Market notifying Urologix that its request had been granted for an additional 180 calendar day cure period, until August 15, 2011, to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The NASDAQ Capital Market,
University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.
Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model.
› Verified 5 days ago
Peter G Mangone, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 60 Livingston St, Suite 100, Asheville, NC 28801 Phone: 828-258-8800 Fax: 828-281-7178 | |
Dr. Keith M Maxwell, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 21 Turtle Creek Dr, Asheville, NC 28803 Phone: 828-274-4555 Fax: 828-274-3615 | |
Dr. Pamela Gutbier Meliski, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 75b Livingston St, Asheville, NC 28801 Phone: 828-258-8800 | |
Dr. Wallace Taylor Harris, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 75b Livingston St, Asheville, NC 28801 Phone: 828-258-8800 | |
Michael J Goebel, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 75b Livingston St, Asheville, NC 28801 Phone: 828-258-8800 Fax: 828-281-7178 | |
Charles M. Lecroy, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1995 | |
Andrew V Prizigley, PA-C Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-255-7776 |